<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04744545</url>
  </required_header>
  <id_info>
    <org_study_id>#20-MERU-106</org_study_id>
    <nct_id>NCT04744545</nct_id>
  </id_info>
  <brief_title>RCT of Adjunctive Curcumin and the Meru Health Program</brief_title>
  <official_title>Randomized Controlled Trial of Adjunctive Curcumin and the Meru Health Program for Adults With Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meru Health, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meru Health, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled trial (RCT) to compare the Meru Health Program plus&#xD;
      adjunctive curcumin (MHP-CUR) versus Meru Health Program only (MHP-ONLY) for adults with&#xD;
      depression. Meru Health is a 12-week integrative treatment program based on several&#xD;
      evidence-based practices and overseen by licensed clinical therapists that is delivered via a&#xD;
      Smartphone app. The primary objective of the study is to determine the feasibility, initial&#xD;
      efficacy (depressive symptoms), and potential harms of taking adjunctive curcumin&#xD;
      supplementation during the 12-week MHP among adults with depression. Secondary objectives&#xD;
      include comparing changes in inflammation biomarkers, anxiety, worker productivity, and&#xD;
      burnout that occur during the program between those in MHP-CUR and MHP-ONLY.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized controlled trial (RCT) to compare the Meru Health Program plus&#xD;
      adjunctive curcumin (MHP-CUR) versus Meru Health Program only (MHP-ONLY) for adults with&#xD;
      depression. Meru Health is a 12-week integrative treatment program based on several&#xD;
      evidence-based practices and overseen by licensed clinical therapists that is delivered via a&#xD;
      Smartphone app. The primary objective of the study is to determine the feasibility, initial&#xD;
      efficacy (depressive symptoms), and potential harms of taking adjunctive curcumin&#xD;
      supplementation during the 12-week MHP among adults with depression. Secondary objectives&#xD;
      include comparing changes in inflammation biomarkers, anxiety, worker productivity, and&#xD;
      burnout that occur during the program between those in MHP-CUR and MHP-ONLY.&#xD;
&#xD;
      This feasibility study will use a randomized controlled trial of up to 60 adult patients with&#xD;
      depression. Patients will be recruited through Facebook ads, complete online and&#xD;
      telephone/Zoom screening and, if eligible, invited to participate in the 12-week Meru Health&#xD;
      program. One group will be randomized to being in the MHP plus receiving curcumin&#xD;
      supplementation (MHP-CUR) and the other will be randomized to being in the MHP only&#xD;
      (MHP-only). The MHP overseen by a licensed therapist who is available to the participant as&#xD;
      needed via text messaging and, when requested, telephone. The program is delivered via an app&#xD;
      downloaded to the user's Smartphone made available via email. The lab orders will be sent to&#xD;
      each patient's Ultalabs center of choice or, if preferred, done in the patient's home. All&#xD;
      study participants (in both groups) will be asked to get their blood drawn before starting&#xD;
      the program, 6 weeks into the program, and just after the 12-week program. Two vials of blood&#xD;
      will be taken at each visit, one to test for high sensitivity-CRP (hs-CRP) levels and the&#xD;
      other to test for interleukin (IL-6) levels. 2ml of serum is needed for each vial. Patients&#xD;
      in both groups will receive a wearable HRVB device via US mail; patients in the MHP-CUR group&#xD;
      will also receive curcumin supplements via US mail. All non-laboratory study assessments will&#xD;
      be made via the app and online via email.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled trial with two study groups.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Outcomes assessors will not have information about each participant's study group.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Depression</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean changes in the Patient Health Questionnaire, 9 item scale (PHQ-9) made during the program will be calculated. Scores range from 0 (no depression) to 27 (most severe depression)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient-reported adverse events</measure>
    <time_frame>during the 12 week program</time_frame>
    <description>The proportion of patients reporting at least one adverse event during the 12-week intervention will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anxiety</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean changes in the Generalized Anxiety Disorder-7 item scale (GAD-7) will be reported. GAD-7 scores range from 0 (no anxiety) to 21 (most severe anxiety)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Burnout</measure>
    <time_frame>12 weeks</time_frame>
    <description>The proportion of patients with changes in burnout will be reported. A validated, single-item burnout question will be used to assess burnout that has 5 response categoreis ranging from 1 (no burnout) to 5 (completed burned out) and dichotomized as &lt;3 (no to low burnout) versus &gt;=3 (at least moderate levels of burnout)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worker productivity and activity impairment</measure>
    <time_frame>12 weeks</time_frame>
    <description>The mean percent difference in each of the 4 subscales of the Worker Productivity and Activity Impairment (WPAI) scale will be reported. Subscales include absenteeism, presenteeism, overall worker productivity impairment, and impairment with daily activities and range from 0 (no impairment) to 100% (complete impairment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapist rating</measure>
    <time_frame>12 weeks</time_frame>
    <description>The proportion of patients who reported being satisfied with their program therapist will be reported as dichotmized by a 5-category scale that ranges from 1 (not at all satisfied) to 5 (extremely satisfied). Responses &quot;1&quot; and &quot;2&quot; (not at all satisfied and not satisfied) will be combined into a &quot;not satisfied&quot; dichotomous category and responses 2 (satisfied), 3 (very satisfied) and 4 (extremely satisfied) will be combined into a &quot;satisfied&quot; dichotomous category, with the proportion of patients falling into each category being reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-6</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean changes in Interleukin-6 (IL-6) will be calculated for each participant to measure changes in inflammation made during the program.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Sensitivity C Reactive Protein</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean changes in high-sensitivity c reactive protein (hs-crp) will be calculated for each participant to measure changes in inflammation made during the program.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Meru Health Program plus adjunctive curcumin (MHP-CUR)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Meru Health Program (12 week program) with participants taking 2 turmeric supplements (1500mg/day) curcumin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Meru Health Program (MHP-ONLY)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Meru Health Program (12 week program)</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Meru Health Program</intervention_name>
    <description>12 week evidence-based mental health intervention overseen by a licensed clinical therapist delivered via Smartphone app</description>
    <arm_group_label>Meru Health Program (MHP-ONLY)</arm_group_label>
    <arm_group_label>Meru Health Program plus adjunctive curcumin (MHP-CUR)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Curcumin</intervention_name>
    <description>1500mg/day curcumin plus black pepper to aid absorption</description>
    <arm_group_label>Meru Health Program plus adjunctive curcumin (MHP-CUR)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  Patient presenting to the Meru Health online clinic&#xD;
&#xD;
          -  Able to read and understand English&#xD;
&#xD;
          -  Own a Smartphone&#xD;
&#xD;
          -  Willing to commit to doing program practices for 10 minutes a day, 6 days a week for&#xD;
             12 weeks&#xD;
&#xD;
          -  PHQ-9 of 10 or higher&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lifetime bipolar disorder or a psychotic disorder&#xD;
&#xD;
          -  Possible cognitive impairment&#xD;
&#xD;
          -  Substance use disorder in the past 3 months&#xD;
&#xD;
          -  Active suicidal ideation with at least some intent to act&#xD;
&#xD;
          -  Pregnant, breastfeeding, or desiring to become pregnant in the next 6 months&#xD;
&#xD;
          -  Self-reported current suffering from a major medical illness including&#xD;
             neurodegenerative/neuroinflammatory disorders, anemia, Alzheimer's disease, stroke,&#xD;
             Parkinson's disease, or multiple sclerosis, autoimmune disorders, diabetes,&#xD;
             inflammatory bowel disease, chronic obstructive pulmonary disease, asthma, coagulation&#xD;
             disorder, cardiovascular disease, hypertension, chronic fatigue syndrome, fibromyalgia&#xD;
&#xD;
          -  Self-reported current use of glucocorticoids, antibiotics, anticoagulant medications,&#xD;
             antioxidant supplements (including curcumin), herbal supplements, or Ï‰3&#xD;
             polyunsaturated fatty acids&#xD;
&#xD;
          -  Self-reported past suffering from an infection or illness over the past month&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Valerie F Hoffman, PhD, MPH</last_name>
    <phone>13193214901</phone>
    <email>valerie@meruhealth.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Online</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie F Hoffman, PhD, MPH</last_name>
      <phone>319-321-4901</phone>
      <email>valerie@meruhealth.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 25, 2021</study_first_submitted>
  <study_first_submitted_qc>February 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2021</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

